We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.42%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.07B
AUM Growth
+$166M
Cap. Flow
+$47.2M
Cap. Flow %
4.41%
Top 10 Hldgs %
29.4%
Holding
105
New
13
Increased
43
Reduced
32
Closed
11

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$17.2M
2
DOCS icon
Doximity
DOCS
+$13.3M
3
AMGN icon
Amgen
AMGN
+$11.4M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
VERA icon
Vera Therapeutics
VERA
+$10.3M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19M
2
CAH icon
Cardinal Health
CAH
+$14.8M
3
ABT icon
Abbott
ABT
+$13.2M
4
CYTK icon
Cytokinetics
CYTK
+$13.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
51
Mirum Pharmaceuticals
MIRM
$6.02B
$8.39M 0.78%
106,255
+50,000
+89% +$3.59M
GH icon
52
Guardant Health
GH
$22.4B
$8.17M 0.76%
80,000
+30,000
+60% +$2.68M
RPRX icon
53
Royalty Pharma
RPRX
$25.8B
$7.98M 0.75%
206,500
-52,000
-20% -$1.98M
BTSG icon
54
BrightSpring Health Services
BTSG
$12.2B
$7.42M 0.69%
198,000
+138,000
+230% +$4.63M
BRKR icon
55
Bruker
BRKR
$8.58B
$6.94M 0.65%
147,315
-7,000
-5% -$296K
STOK icon
56
Stoke Therapeutics
STOK
$2.08B
$6.86M 0.64%
216,000
-34,000
-14% -$1.02M
BBIO icon
57
BridgeBio Pharma
BBIO
$16.6B
$6.24M 0.58%
+81,600
New +$5.36M
XENE icon
58
Xenon Pharmaceuticals
XENE
$6.21B
$6.23M 0.58%
139,000
+58,000
+72% +$2.44M
AVR
59
Anteris Technologies
AVR
$872M
$6.18M 0.58%
1,238,625
-12,138
-1% -$55.7K
KRYS icon
60
Krystal Biotech
KRYS
$9.81B
$6.16M 0.58%
25,000
+13,250
+113% +$2.79M
IQV icon
61
IQVIA
IQV
$39.8B
$5.97M 0.56%
26,500
+7,000
+36% +$1.52M
IMCR icon
62
Immunocore
IMCR
$1.73B
$5.32M 0.5%
153,278
+125,000
+442% +$4.41M
ELV icon
63
Elevance Health
ELV
$86.2B
$5.26M 0.49%
15,000
-7,500
-33% -$2.53M
MLYS icon
64
Mineralys Therapeutics
MLYS
$2.41B
$5.17M 0.48%
142,571
-22,429
-14% -$899K
MLTX icon
65
MoonLake Immunotherapeutics
MLTX
$1.47B
$4.8M 0.45%
364,000
+157,000
+76% +$1.85M
CRL icon
66
Charles River Laboratories
CRL
$13.2B
$4.39M 0.41%
+22,000
New +$3.99M
IOVA icon
67
Iovance Biotherapeutics
IOVA
$2.9B
$4.36M 0.41%
1,595,327
+497,500
+45% +$1.15M
VCEL icon
68
Vericel Corp
VCEL
$2.25B
$4.21M 0.39%
117,000
– –
DNTH icon
69
Dianthus Therapeutics
DNTH
$6.25B
$4.06M 0.38%
98,627
-75,000
-43% -$2.91M
RLAY icon
70
Relay Therapeutics
RLAY
$4.37B
$3.89M 0.36%
460,000
– –
RYTM icon
71
Rhythm Pharmaceuticals
RYTM
$7.95B
$3.75M 0.35%
35,000
– –
OSCR icon
72
Oscar Health
OSCR
$8.54B
$3.74M 0.35%
+260,000
New +$4.5M
ALKS icon
73
Alkermes
ALKS
$8.29B
$3.73M 0.35%
133,250
+39,250
+42% +$1.18M
RDNT icon
74
RadNet
RDNT
$6.08B
$3.35M 0.31%
47,000
-3,000
-6% -$232K
INSP icon
75
Inspire Medical Systems
INSP
$1.73B
$3.3M 0.31%
35,800
-25,200
-41% -$2.41M
1 2
3
4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Rhenman & Partners Asset Management held 105 positions worth $1.07B, up 18% from $904M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $47.2M of net new capital in Q4 2025, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Amgen: 36,000 shares worth $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $13.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2025 buy was Amgen: 36,000 shares worth $11.8M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q4 2025, an estimated $17.2M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $13.1M.
  • Rhenman & Partners Asset Management fully exited Exact Sciences in Q4 2025, selling an estimated $19M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.07B portfolio in Q4 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q4 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.07B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.